Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational study of dapagliflozin in IgA nephropathy
jRCT1031220369Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dapagliflozin in IgA nephropathy (IgAN), sponsored by AstraZeneca. Primary endpoints: Change in proteinuria from baseline and Change in eGFR from baseline. Started Nov 2021; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT1031220369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220369.